tiprankstipranks
Sarepta Therapeutics Inc. (MX:SRPT)
NASDAQ:SRPT
Mexico Market
SRPT
Sarepta Therapeutics
RESEARCH TOOLSreports

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

SRPT Analyst Ratings

Hold
16Ratings
Hold
5 Buy
7 Hold
4 Sell
Based on 16 analysts giving stock ratings to
Sarepta
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SRPT Stock 12 Month Forecast

Average Price Target

$398.63
Based on 16 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $398.63 with a high forecast of $660.52 and a low forecast of $86.91. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"85":"$85","229":"$229","373":"$373","517":"$517","661":"$661"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":660.52494368,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$660.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":398.6325975893334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$398.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86.9111768,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$86.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[85,229,373,517,661],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,294,322.1942264369231,350.3884528738462,378.5826793107692,406.7769057476923,434.9711321846154,463.1653586215384,491.3595850584615,519.5538114953846,547.7480379323076,575.9422643692308,604.1364908061538,632.3307172430768,{"y":660.52494368,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,294,302.04866135302564,310.0973227060513,318.1459840590769,326.1946454121026,334.24330676512824,342.2919681181539,350.3406294711795,358.38929082420515,366.43795217723084,374.4866135302565,382.5352748832821,390.58393623630775,{"y":398.6325975893334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,294,278.07009052307694,262.1401810461538,246.21027156923077,230.2803620923077,214.35045261538463,198.42054313846154,182.49063366153848,166.5607241846154,150.6308147076923,134.70090523076925,118.77099575384617,102.84108627692308,{"y":86.9111768,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":338.91,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 67, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 81, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 27</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":339.43,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 69, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 26</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":359.99,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":450,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":359,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":395,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":361,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":361,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":360,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":364,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$660.52Average Price Target$398.63Lowest Price Target$86.91
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on MX:SRPT
Yigal Nochomovitz
Citi
Citi
$225.97
Sell
―
Reiterated
07/20/26
Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13
Bank of America Securities Analyst forecast on MX:SRPT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$330.26
Sell
―
Reiterated
07/15/26
Bank of America Securities Sticks to Its Sell Rating for Sarepta Therapeutics (SRPT)
Mizuho Securities Analyst forecast on MX:SRPT
Uy Ear
Mizuho Securities
Mizuho Securities
$538.85
Buy
―
Reiterated
07/10/26
Analysts Offer Insights on Healthcare Companies: Forte Biosciences (NASDAQ: FBRX), Sarepta Therapeutics (NASDAQ: SRPT) and Opus Genetics (NASDAQ: IRD)
Piper Sandler Analyst forecast on MX:SRPT
Biren Amin
Piper Sandler
Piper Sandler
$347.64
Hold
―
Assigned
07/09/26
Sarepta price target lowered to $20 from $23 at Piper SandlerSarepta price target lowered to $20 from $23 at Piper Sandler
Wolfe Research Analyst forecast on MX:SRPT
Andy Chen
Wolfe Research
Wolfe Research
$469.32
Buy
―
Upgraded
07/08/26
Sarepta upgraded to Outperform from Peer Perform at Wolfe ResearchSarepta upgraded to Outperform from Peer Perform at Wolfe Research
RBC Capital Analyst forecast on MX:SRPT
Brian Abrahams
RBC Capital
RBC Capital
$330.26
Hold
―
Reiterated
07/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Healthequity (NASDAQ: HQY), Sarepta Therapeutics (NASDAQ: SRPT) and COMPASS Pathways (NASDAQ: CMPS)
H.C. Wainwright Analyst forecast on MX:SRPT
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$86.91
Sell
―
Reiterated
07/01/26
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Niagen Bioscience (NASDAQ: NAGE) and AC Immune SA (NASDAQ: ACIU)
Morgan Stanley Analyst forecast on MX:SRPT
Michael Ulz
Morgan Stanley
Morgan Stanley
$434.56
Hold
―
Reiterated
06/30/26
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Illumina (NASDAQ: ILMN) and Protara Therapeutics (NASDAQ: TARA)
Wedbush Analyst forecast on MX:SRPT
Yun Zhong
Wedbush
Wedbush
$608.38
Buy
―
Reiterated
06/30/26
Analysts' Top Healthcare Picks: Palisade Bio (PALI), Sarepta Therapeutics (SRPT)
Barclays Analyst forecast on MX:SRPT
Eliana Merle
Barclays
Barclays
$347.64
Hold
―
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Eli Lilly & Co (NYSE: LLY) and C4 Therapeutics (NASDAQ: CCCC)
J.P. Morgan Analyst forecast on MX:SRPT
Anupam Rama
J.P. Morgan
J.P. Morgan
$312.88→$330.26
Hold
―
Reiterated
05/18/26
J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)
Evercore ISI Analyst forecast on MX:SRPT
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$347.64→$330.26
Hold
―
Reiterated
05/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (NYSE: ZTS), Sarepta Therapeutics (NASDAQ: SRPT) and GoodRx Holdings (NASDAQ: GDRX)
TD Cowen Analyst forecast on MX:SRPT
Ritu Baral
TD Cowen
TD Cowen
$295.5
Hold
―
Reiterated
05/07/26
Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
Needham Analyst forecast on MX:SRPT
Gil Blum
Needham
Needham
―
Sell
―
Reiterated
05/07/26
Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
Wells Fargo Analyst forecast on MX:SRPT
Yanan Zhu
Wells Fargo
Wells Fargo
$660.52
Buy
―
Reiterated
05/07/26
Wells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on MX:SRPT
Yigal Nochomovitz
Citi
Citi
$225.97
Sell
―
Reiterated
07/20/26
Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13
Bank of America Securities Analyst forecast on MX:SRPT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$330.26
Sell
―
Reiterated
07/15/26
Bank of America Securities Sticks to Its Sell Rating for Sarepta Therapeutics (SRPT)
Mizuho Securities Analyst forecast on MX:SRPT
Uy Ear
Mizuho Securities
Mizuho Securities
$538.85
Buy
―
Reiterated
07/10/26
Analysts Offer Insights on Healthcare Companies: Forte Biosciences (NASDAQ: FBRX), Sarepta Therapeutics (NASDAQ: SRPT) and Opus Genetics (NASDAQ: IRD)
Piper Sandler Analyst forecast on MX:SRPT
Biren Amin
Piper Sandler
Piper Sandler
$347.64
Hold
―
Assigned
07/09/26
Sarepta price target lowered to $20 from $23 at Piper SandlerSarepta price target lowered to $20 from $23 at Piper Sandler
Wolfe Research Analyst forecast on MX:SRPT
Andy Chen
Wolfe Research
Wolfe Research
$469.32
Buy
―
Upgraded
07/08/26
Sarepta upgraded to Outperform from Peer Perform at Wolfe ResearchSarepta upgraded to Outperform from Peer Perform at Wolfe Research
RBC Capital Analyst forecast on MX:SRPT
Brian Abrahams
RBC Capital
RBC Capital
$330.26
Hold
―
Reiterated
07/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Healthequity (NASDAQ: HQY), Sarepta Therapeutics (NASDAQ: SRPT) and COMPASS Pathways (NASDAQ: CMPS)
H.C. Wainwright Analyst forecast on MX:SRPT
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$86.91
Sell
―
Reiterated
07/01/26
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Niagen Bioscience (NASDAQ: NAGE) and AC Immune SA (NASDAQ: ACIU)
Morgan Stanley Analyst forecast on MX:SRPT
Michael Ulz
Morgan Stanley
Morgan Stanley
$434.56
Hold
―
Reiterated
06/30/26
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Illumina (NASDAQ: ILMN) and Protara Therapeutics (NASDAQ: TARA)
Wedbush Analyst forecast on MX:SRPT
Yun Zhong
Wedbush
Wedbush
$608.38
Buy
―
Reiterated
06/30/26
Analysts' Top Healthcare Picks: Palisade Bio (PALI), Sarepta Therapeutics (SRPT)
Barclays Analyst forecast on MX:SRPT
Eliana Merle
Barclays
Barclays
$347.64
Hold
―
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Eli Lilly & Co (NYSE: LLY) and C4 Therapeutics (NASDAQ: CCCC)
J.P. Morgan Analyst forecast on MX:SRPT
Anupam Rama
J.P. Morgan
J.P. Morgan
$312.88→$330.26
Hold
―
Reiterated
05/18/26
J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)
Evercore ISI Analyst forecast on MX:SRPT
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$347.64→$330.26
Hold
―
Reiterated
05/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (NYSE: ZTS), Sarepta Therapeutics (NASDAQ: SRPT) and GoodRx Holdings (NASDAQ: GDRX)
TD Cowen Analyst forecast on MX:SRPT
Ritu Baral
TD Cowen
TD Cowen
$295.5
Hold
―
Reiterated
05/07/26
Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
Needham Analyst forecast on MX:SRPT
Gil Blum
Needham
Needham
―
Sell
―
Reiterated
05/07/26
Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
Wells Fargo Analyst forecast on MX:SRPT
Yanan Zhu
Wells Fargo
Wells Fargo
$660.52
Buy
―
Reiterated
05/07/26
Wells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
GKOSGlaukos
ARDXArdelyx
STOKStoke Therapeutics
MIRMMirum Pharmaceuticals
CSTLCastle Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sarepta Therapeutics

3 Months
Debjit ChattopadhyayGuggenheim
Success Rate
20/35 ratings generated profit
57%
Average Return
+8.13%
Copying Debjit Chattopadhyay's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +8.13% per trade.
1 Year
Yun ZhongWedbush
Success Rate
13/24 ratings generated profit
54%
Average Return
+7.71%
Copying Yun Zhong's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +7.71% per trade.
2 Years
Gil BlumNeedham
Success Rate
13/31 ratings generated profit
42%
Average Return
-29.35%
Copying Gil Blum's trades and holding each position for 2 Years would result in 41.94% of your transactions generating a profit, with an average return of -29.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRPT Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
13
14
16
8
6
Buy
8
4
4
1
2
Hold
31
23
18
12
12
Sell
11
7
7
2
4
Strong Sell
6
4
4
2
2
total
69
52
49
25
26
In the current month, SRPT has received 8 Buy Ratings, 12 Hold Ratings, and 6 Sell Ratings. SRPT average Analyst price target in the past 3 months is 398.63.
Each month's total comprises the sum of three months' worth of ratings.

SRPT Financial Forecast

SRPT Earnings Forecast

Next quarter’s earnings estimate for SRPT is $3.80 with a range of -$2.98 to $15.41. The previous quarter’s EPS was $50.43. SRPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.
Next quarter’s earnings estimate for SRPT is $3.80 with a range of -$2.98 to $15.41. The previous quarter’s EPS was $50.43. SRPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Sales Forecast

Next quarter’s sales forecast for SRPT is $6.69B with a range of $5.65B to $11.93B. The previous quarter’s sales results were $12.80B. SRPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.
Next quarter’s sales forecast for SRPT is $6.69B with a range of $5.65B to $11.93B. The previous quarter’s sales results were $12.80B. SRPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Stock Forecast FAQ

What is MX:SRPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics Inc.’s 12-month average price target is 398.63.
    What is MX:SRPT’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:SRPT, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Sarepta Therapeutics Inc. a Buy, Sell or Hold?
        Sarepta Therapeutics Inc. has a consensus rating of Hold, which is based on 5 buy ratings, 7 hold ratings and 4 sell ratings.
          What is Sarepta Therapeutics Inc.’s share price target?
          The average share price target for Sarepta Therapeutics Inc. is 398.63. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $660.52 ,and the lowest forecast is $86.91. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Sarepta Therapeutics Inc.?
            Sarepta Therapeutics Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 16 Wall Streets Analysts.
              How can I buy shares of Sarepta Therapeutics Inc.?
              To buy shares of MX:SRPT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.